Articles

Systematic literature review finds substantial variability in patient characteristics and response rates across DLBCL trials Read More ›

Medicare Advantage claims analysis explores economic burden of cancer by type and stage, underscoring the importance of early detection Read More ›

Analysis of health plans examines the variability in specialty drug coverage among medical and pharmacy benefit policies Read More ›

Analysis of clinical practice guidelines identified 10 good practice recommendations for engaging patients in the development process Read More ›

Analysis of circulating tumor DNA can identify patients at high risk of early disease progression who could benefit from combining immune checkpoint inhibitors with chemotherapy. Read More ›

A highly multiplexed proteomic assay was developed to guide treatment selection for patients with lung cancer. Read More ›

Implementing a machine learning–based system that integrates radiologic, pathologic, and genomic data to predict response to PD-1 blockade may be able to outperform conventional unimodal approaches. Read More ›

Mechanisms of acquired resistance to anti–PD-(L)1 therapy in patients with advanced NSCLC are heterogeneous and require novel therapeutic strategies to be surmounted. Read More ›

Administering nivolumab in the morning improved progression-free survival and overall survival compared with administration during later times of the day, suggesting that circadian rhythm may affect its efficacy. Read More ›

Patients with NSCLC with poor performance status (PS) had significantly worse survival outcomes and were more likely to utilize healthcare services than those with favorable PS. Read More ›